Your browser doesn't support javascript.
loading
Technical Decision Making With Higher Order Structure Data: Perspectives on Higher Order Structure Characterization From the Biopharmaceutical Industry.
Weiss, William F; Gabrielson, John P; Al-Azzam, Wasfi; Chen, Guodong; Davis, Darryl L; Das, Tapan K; Hayes, David B; Houde, Damian; Singh, Satish K.
Affiliation
  • Weiss WF; Biopharmaceutical Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285. Electronic address: weisswf@lilly.com.
  • Gabrielson JP; Elion Labs, 1450 Infinite Drive, Louisville, Colorado 80027.
  • Al-Azzam W; BioPharm Analytical Sciences, Biopharmaceutical Development R&D, GlaxoSmithKline, King of Prussia, Pennsylvania 19406.
  • Chen G; Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543.
  • Davis DL; Janssen Research & Development LLC, Spring House, Pennsylvania 19477.
  • Das TK; Biologics Development, Bristol-Myers Squibb Company, Pennington, New Jersey 08534.
  • Hayes DB; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877.
  • Houde D; Protein Pharmaceutical Development, Biogen, Cambridge, Massachusetts 02142.
  • Singh SK; Biotherapeutics Pharmaceutical Sciences, Pfizer, Inc., Chesterfield, Missouri 63017.
J Pharm Sci ; 105(12): 3465-3470, 2016 12.
Article in En | MEDLINE | ID: mdl-27743675
ABSTRACT
Characterization of the higher order structure (HOS) of protein-based biopharmaceutical products is an important aspect of their development. Opinions vary about how best to apply biophysical methods, in which contexts to use these methods, and how to use the resulting data to make technical decisions as drug candidates are commercialized [Gabrielson JP, Weiss WF IV. J Pharm Sci. 2015;104(4)1240-1245]. The aim of this commentary is to provide guidance for the development and implementation of a robust and comprehensive HOS characterization strategy. We first consider important concepts involved in developing a strategy that is appropriately suited to a particular biologic, and then discuss ways industry can partner with academia, technology companies, government laboratories, and regulatory agencies to improve the consistency with which HOS characterization is applied across the biopharmaceutical industry.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Products / Statistics as Topic / Technology, Pharmaceutical / Decision Making / Drug Industry Limits: Animals / Humans Language: En Journal: J Pharm Sci Year: 2016 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Products / Statistics as Topic / Technology, Pharmaceutical / Decision Making / Drug Industry Limits: Animals / Humans Language: En Journal: J Pharm Sci Year: 2016 Document type: Article